HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Decreases in Rhinology Care Utilization by People with Cystic Fibrosis on Highly Effective Modulator Therapy.

AbstractBACKGROUND:
Many people with cystic fibrosis (PwCF) have chronic rhinosinusitis (CRS). CRS requires additional management beyond that of pulmonary disease and leads to increased utilization of healthcare resources. Elexacaftor/tezacaftor/ivacaftor (ETI) is a highly effective modulator therapy that has been shown to improve CRS in PwCF. However, the impact of ETI on rhinologic healthcare utilization is understudied.
OBJECTIVE:
To compare rates of rhinologic healthcare utilization and procedures among PwCF prior to and after initiating ETI therapy.
METHODS:
A single-center, cohort study investigating adult PwCF was performed in January 2023. Demographics, clinical characteristics, and data related to CF treatment were retrospectively abstracted. Characteristics of the cohort were compared over 2 periods: the 12-months prior to ETI initiation and the 12-months after ETI initiation. Post-ETI data were linearly extrapolated if a subject had not yet completed the full 12 months of ETI. Paired t-testing, Wilcoxon signed rank testing, and regression analysis were performed.
RESULTS:
Of 126 PwCF, 98 (77.8%) were on ETI therapy and 35 (27.7%) were both on ETI and concurrently followed by the rhinology service (ETI-ENT). Rhinology clinic visits (P = .007) and frequency of obtaining nasal cultures (P = .046) decreased for the ETI-ENT cohort after initiating ETI treatment. There were no significant changes in the number of endoscopic sinus surgeries (P = .452) performed. Beyond ETI use, regression analysis did not identify any factors associated with changes in utilization.
CONCLUSION:
Aspects of rhinology healthcare utilization by PwCF decreased after initiation of ETI therapy. Additional studies are needed to determine rhinologic healthcare requirements for PwCF who remain on ETI for the long-term and to evaluate larger cohorts of PwCF on ETI.
AuthorsEthan J Han, Daniel M Beswick, Patricia H Eshaghian, Grant A Turner, Jivianne T Lee, Douglas A Li, Marilene B Wang, Jennifer L Taylor-Cousar, Jeffrey D Suh
JournalThe Annals of otology, rhinology, and laryngology (Ann Otol Rhinol Laryngol) Vol. 133 Issue 3 Pg. 340-344 (Mar 2024) ISSN: 1943-572X [Electronic] United States
PMID37953524 (Publication Type: Journal Article)
Topics
  • Adult
  • Humans
  • Cystic Fibrosis (complications, therapy)
  • Cohort Studies
  • Retrospective Studies
  • Ambulatory Care
  • Nose
  • Mutation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: